SYRS (Syros Pharmaceuticals) Change In Receivables : $1.67 Mil (TTM As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Change In Receivables?

Syros Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Syros Pharmaceuticals's Accounts Receivable stayed the same from Jun. 2024 to Sep. 2024 .

Syros Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $1.69 Mil. It means Syros Pharmaceuticals's Accounts Receivable declined by $1.69 Mil from Dec. 2022 to Dec. 2023 .

Syros Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Syros Pharmaceuticals's liquidation value for the three months ended in Sep. 2024 was $-37.84 Mil.

Syros Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Syros Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Change In Receivables Chart

Syros Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-20.16

17.83

-0.65

1.29

1.69

Syros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															0.09	1.67	-	-	-

Syros Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.67 Mil.

Syros Pharmaceuticals (NAS:SYRS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Syros Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Syros Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Syros Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	58.275	-	96.118	+	0.75 * 0	+	0.5 * 0
=	-37.84

Syros Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

0LC7:UK 0S90:Germany

Address

35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140

Website

https://www.syros.com

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Executives

Nancy A Simonian	director, 10 percent owner, officer: President & CEO	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk	officer: Chief Legal Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth	officer: Chief Medical Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas	officer: Chief Financial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens	officer: Chief Development Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley	officer: Chief Commercial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson	officer: Chief Scientific Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson	director	ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh	director	C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn	officer: Chief Business Officer	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421